Novel target and mab candidates for the treatment of hcmv infection

The present invention relates to a method for treating an infection, particularly HCMV infection. To date, there are very few reports on the role of DC-SIGN+ dendritic cells in very early phases of viral infections. By using four anti-human DC-SIGN monoclonal antibodies, the inventors have demonstrated that DC-SIGN might be considered as the most important receptor for both pre- and post-fusion HCMV gB on monocyte-derived dendritic cells (MDDCs). In particular, the invention relates to a method for treating an infection in a subject in need thereof comprising a step of administering to said subject an agent that blocks the interaction between DC-SIGN and an infectious ligand.

Keywords: Infectious Diseases, Antivirals, HCMV, DC-SIGN
Patent Application number: EP17305064.2
Inventors:
Jean-Jacques PINFranck HALARYDiane RAZANAJAONA-DOLL
Publications:
Org Biomol Chem. 2017 Sep 20;15(36):7660-7671. doi: 10.1039/c7ob01569k.

Reference:

BIO16304-T1

Business Developper
contact
Elodie Acloque
Elodie Acloque
Business Developer
Patent filling date: 23-01-2017

You might also be interested in